Anavex Life Sciences Corp. (AVXL)
NASDAQ: AVXL · Real-Time Price · USD
8.67
+0.76 (9.61%)
Mar 3, 2025, 12:39 PM EST - Market open
Anavex Life Sciences Employees
Anavex Life Sciences had 42 employees as of September 30, 2024. The number of employees increased by 2 or 5.00% compared to the previous year.
Employees
42
Change (1Y)
2
Growth (1Y)
5.00%
Revenue / Employee
n/a
Profits / Employee
-$1,106,929
Market Cap
737.51M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 131,900 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 72,000 |
AVXL News
- 7 days ago - Anavex Life Sciences to Present at the 45th Annual TD Cowen Health Care Conference - GlobeNewsWire
- 16 days ago - Anavex: Looking At Different Statistical Approaches Before EMA Opinion - Seeking Alpha
- 18 days ago - Anavex: Further Validation Of Blarcamesine With Schizophrenia Data In 2025 - Seeking Alpha
- 19 days ago - Anavex Life Sciences Corp. (AVXL) Q1 2025 Earnings Call Transcript - Seeking Alpha
- 19 days ago - Anavex Life Sciences Reports Fiscal 2025 First Quarter Financial Results and Provides Business Update - GlobeNewsWire
- 26 days ago - Anavex Life Sciences to Announce Fiscal 2025 First Quarter Financial Results on Wednesday, February 12, 2025 - GlobeNewsWire
- 5 weeks ago - Anavex Life Sciences Announces Issuance of Blarcamesine (ANAVEX®2-73) Composition of Matter U.S. Patent Expanding its Intellectual Property Portfolio - GlobeNewsWire
- 6 weeks ago - Anavex Life Sciences Announces Peer-Reviewed Publication of Oral Blarcamesine Phase IIb/III Data in The Journal of Prevention of Alzheimer's Disease - GlobeNewsWire